Nymox Pharmaceutical Corporation (NYMX) Return on Investment ROI from the fourth quarter of 2024 to fourth quarter of 2023 and for the year 2024, average high and low, overall ranking from Dec 31 2024 to Dec 31 2023 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Nymox Pharmaceutical Corporation  (NYMX)


Nymox Pharmaceutical's ROI from its fourth quarter of 2024 to the fourth quarter of 2023 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Nymox Pharmaceutical's ROI in the fourth quarter of 2024?
Due to the stockholders deficit and subsequent negative measured investments, it was not possible to calculate Nymox Pharmaceutical Corporation's return on investment (ROI) in its fourth quarter of 2024

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Dec 31 2024)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2023)
IV. Quarter
Y / Y Investment Change TTM - - - - -
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions -7 -6 -7 -7 -3
Return On Investment (TTM) - - - - -
NYMX's Overall Ranking # # # # #
Seq. Investment Change TTM - - - - -
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -4 -9 -9 -9 -10

NYMX Company Profile >> Back to NYMX Roi Comparisons >> See Annual NYMX Return On Investment



Return On Investment NYMX's Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Investment Statistics
High Average Low
0 %
0 %
0 %
 







Financial Statements
Nymox Pharmaceutical's IV. Quarter Investments $ -7 Millions NYMX's Balance sheet
Nymox Pharmaceutical's IV. Quarter Income $ -4 Millions Quarterly NYMX's Income Statement
NYMX's Income by Division See NYMX's Income by Division


NYMX Annual Return On Investment (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020
Total Investments in Millions -7 -3 0 0 3
Y / Y Investment Growth - - - - -44.41 %
Net Income in Millions -4 -9 -7 -13 -12
Y / Y Net Income Growth - - - - -
Annual Return On Investment - - - - -467.09 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
In Vitro & In Vivo Diagnostic Substances Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
NYMX's Roi Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for NYMX's Competitors
Subscribers only: Roi for Nymox Pharmaceutical's Suppliers
Subscribers only: Return On Investment for NYMX's Customers

Other Ratios
NYMX's Roa NYMX's Inventory Turnover Ratio NYMX's Growth Rates NYMX's Dividend Statistics
NYMX's Profitability Ratios NYMX's Asset Turnover Ratio NYMX's Dividend Growth
NYMX's Roe NYMX's Valuation Ratios NYMX's Financial Strength Ratios NYMX's Dividend Payout Ratio



Companies with similar Return On Investment at Dec 31 2024, within Healthcare Sector ROI
Alumis inc   156.42 %
Longduoduo Co Ltd  152.69 %
Pavmed Inc   149.32 %
Champions Oncology Inc   127.02 %
Cytomx Therapeutics Inc   114.82 %
Oak Woods Acquisition Corp  84.43 %
Earth Science Tech Inc   81.05 %
Addex Therapeutics Ltd  75.10 %
Tao Synergies Inc   71.64 %
Gridai Technologies Corp  62.11 %
Adma Biologics Inc   57.87 %
Agios Pharmaceuticals Inc   56.44 %
Exelixis Inc   48.27 %
Biomx Inc  47.46 %
Galmed Pharmaceuticals Ltd   45.92 %
Protagonist Therapeutics inc   45.50 %
Sbc Medical Group Holdings Incorporated  44.70 %
Mettler toledo International Inc   41.47 %
Edwards Lifesciences Corporation  41.33 %
Dariohealth Corp   40.59 %
Idexx Laboratories Inc  37.76 %
Medpace Holdings Inc   37.38 %
Acadia Pharmaceuticals Inc   35.85 %
Semler Scientific inc   34.43 %
Pharmacyte Biotech Inc   32.98 %
Siga Technologies Inc  32.37 %
Hims and Hers Health Inc   30.09 %
Promis Neurosciences inc   29.63 %
Nrc Health  29.39 %
Entrada Therapeutics Inc   29.29 %

Date modified: 2026-08-31T09:28:23+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.